GPBAR1 and liver disorder: How these compounds affect cholestasis liver disease may not be directly known, but current agonist development is still limited to the GPBAR1 exposure range, and more experiments are needed to explore nonsystemic GPBAR1 agonists, which seems to suggest that existing agonists do not have completely specific targets.